Chimeric Therapeutics is trading 5.26% up now at A$0.02 after resuming trading on August 19, 2026, following disclosure that enrolment and dosing ceased; the gain appears a rebound from the post-announcement selloff, rather than a new clinical catalyst.
- CHM-2101 Phase 1 dosing and enrolment ceased after a second dose-limiting toxicity at Dose Level 3.
- The company is shifting toward in-vivo CDH17 and expects approximately A$4 million in annual cost reductions.
- Biotech strength provided support; the trial update remains dominant.